Expanded access program (EAP) to investigational drugs.

被引：0
|
作者：
Talarico, L [1 ]
Pazdur, R [1 ]
机构：
[1] US FDA, Rockville, MD 20857 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6001
引用
收藏
页码：519S / 519S
页数：1
相关论文
共 50 条
  • [21] The ‘false hope’ argument in discussions on expanded access to investigational drugs: a critical assessment
    Marjolijn Hordijk
    Stefan F. Vermeulen
    Eline M. Bunnik
    Medicine, Health Care and Philosophy, 2022, 25 : 693 - 701
  • [22] Expanded access to investigational drugs: balancing patient safety with potential therapeutic benefits
    Fountzilas, Elena
    Said, Rabih
    Tsimberidou, Apostolia M.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2018, 27 (02) : 155 - 162
  • [23] Ipilimumab retreatment following induction therapy: The expanded access program (EAP) experience
    Margolin, Kim Allyson
    Hamid, Omid
    Weber, Jeffrey S.
    Pavlick, Anna C.
    Hodi, F. Stephen
    Amin, Asim
    Bennett, Kelly
    Michener, Tracy
    Minor, David R.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [24] NUSINERSEN FOR SMA1: THE ITALIAN EXPANDED ACCESS PROGRAM (EAP) EXPERIENCE
    Albamonte, E.
    Pane, M.
    Messina, S.
    D'Amico
    Bertini, E.
    Bruno, C.
    Vita, G.
    Casiraghi, J.
    Binetti, L.
    Mercuri, E.
    Sansone, V. A.
    MUSCLE & NERVE, 2017, 56 : S2 - S3
  • [25] Adapting an Expanded Access program to enable investigational treatments for COVID-19
    Samuels, Elias
    Champagne, Ellen
    Gravelin, Misty
    Racklyeft, Jamie
    Weatherwax, Kevin
    JOURNAL OF CLINICAL AND TRANSLATIONAL SCIENCE, 2022, 6 (01)
  • [26] The Compassionate Use Advisory Committee (CornpAC) for development of pre-approval access to investigational drugs.
    Mitchell, Edith P.
    Caplan, Arthur
    Bateman-House, Alison
    Ray, Amrit
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [27] A study on the long-term survivors in an expanded access program (EAP) of gefitinib in China
    Longyun, L.
    Hui, G.
    Wang, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [28] The use of nusinersen in the "real world": the UK and Ireland experience with the expanded access program (EAP)
    Scoto, M.
    Manzue, A.
    Main, M.
    Munot, P.
    Tillmann, R.
    Bettolo, C. Marini
    Mayhew, A.
    Muni-Lofra, R.
    White, K.
    Baxter, P.
    Tirupathi, S.
    Douglas, I.
    Douglas, M.
    Macauley, S.
    Childs, A-M
    O'Rourke, D.
    Hartley, L.
    Hughes, I.
    McCullagh, G.
    Spinty, S.
    Madhu, R.
    Gregson, S.
    Gowda, V.
    Wraige, E.
    Horrocks, I.
    Brunklaus, A.
    Di Marco, M.
    Dunne, J.
    Brown, S.
    Mochrie, R.
    Illingworth, M.
    Krishnakumar, D.
    Kirkpatrick, M.
    Ramdas, S.
    Vijayakumar, K.
    Selby, V.
    Kulshrestha, R.
    Willis, T.
    Straub, V.
    Muntoni, F.
    NEUROMUSCULAR DISORDERS, 2018, 28 : S25 - S25
  • [29] NeuroREACH™ Platform for Expanded Access Program (EAP) Trials as the Foundation for Clinical Research of the Future
    Sherman, Alexander
    Podesta, Amanda
    Walker, Jason
    Yu, Hong
    D'Agostino, Derek
    Tarasenko, Natalia
    Sinani, Ervin
    Luppino, Sarah
    Scalia, Jennifer
    Paganoni, Sabrina
    Cudkowicz, Merit
    NEUROLOGY, 2020, 94 (15)
  • [30] Access to investigational drugs in the USA
    不详
    LANCET, 2007, 370 (9587): : 540 - 540
12345